phase III trial

BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...

REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2026 — Genentech announced positive Phase III clinical trial results showing that Gazyva®...

AUSTIN, Texas, Feb. 12, 2026 — IntraBio announced positive topline results from its pivotal Phase III IB1001-303 clinical trial...

Toronto, Ontario, January 16, 2026 — Cardiol Therapeutics announced a bought deal private placement financing for gross proceeds of...

BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...

September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...